| 1 |
17308271 | Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. | 2007 Feb 20 |
1 |
| 2 |
16675575 | Effect of calcitriol on prostate-specific antigen in vitro and in humans. | 2006 May 1 |
3 |
| 3 |
16779800 | A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. | 2006 Jul 15 |
1 |
| 4 |
15749627 | Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. | 2005 |
1 |
| 5 |
16104901 | ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. | 2005 Sep |
1 |
| 6 |
12599228 | High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. | 2003 Mar 1 |
1 |
| 7 |
12899524 | The role of vitamin D in prostate cancer. | 2003 |
2 |
| 8 |
11685729 | Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. | 2001 Aug |
1 |
| 9 |
9598513 | Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) | 1998 Jun |
4 |
| 10 |
9231780 | 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. | 1997 Aug |
6 |
| 11 |
8827086 | The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. | 1996 Sep |
1 |
| 12 |
7682937 | Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. | 1993 May |
1 |